Oncosil Medical
Oncosil Medical is a medical device company focused on the development and commercialization of innovative cancer treatments. Their primary product, OncoSil, is a brachytherapy device containing radioactive phosphorus-32, designed for the treatment of locally advanced pancreatic cancer. The company aims to improve patient outcomes and quality of life through targeted radiation therapy.
Short position
Oncosil Medical (ASX:OSL) has 0.00% of its shares on issue reported as short positions as of 5 Oct 2026, or about 66 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.69% in December 2024. OSL is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Oncosil Medical (OSL) short interest history
OSL Short Interest History
- 30-day change
- -0.00pp
- 90-day change
- -0.02pp
- 1-year change
- -0.00pp
- All-time high
- 0.69% (December 2024)
- All-time low
- 0.00% (July 2026)
Is OSL heavily shorted?
Not especially: 0.00% short interest is modest by ASX standards, ranking #721 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has OSL's short interest changed recently?
Over the past 30 days Oncosil Medical's short interest has been broadly stable, and over 90 days it has been broadly stable. The current level is 0.00% of shares on issue.
What is the highest OSL's short interest has been?
Since 2013, Oncosil Medical's short interest peaked at 0.69% in December 2024 and bottomed at 0.00% in July 2026.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2013. See our methodology.